Alpha 2.0
Login Register
» Articles » PMID: 29926311

Andexanet Alfa: First Global Approval

Overview
Journal Drugs
Specialty Pharmacology
Date 2018 Jun 22
PMID 29926311
Citations 36
Authors
Young-A Heo
Affiliations
Soon will be listed here.
Abstract

Intravenous andexanet alfa [coagulation factor Xa (recombinant), inactivated-zhzo; Andexxa] is a first-in-class recombinant modified factor Xa protein that has been developed by Portola Pharmaceuticals as a universal antidote to reverse anticoagulant effects of direct or indirect factor Xa inhibitors. In May 2018, andexanet alfa received its first global approval in the USA for use in patients treated with rivaroxaban and apixaban, when reversal of anticoagulant effects is required in life-threatening or uncontrolled bleeding. Intravenous andexanet alfa is under regulatory review in the EU and is undergoing clinical development in Japan. This article summarizes the milestones in the development of andexanet alfa leading to this first global approval for reversing anticoagulation of rivaroxaban and apixaban in adults.

Citing Articles

Reversal of Direct Oral Anticoagulants (DOACs) for Critical Bleeding or Urgent Procedures.

Goldin M, Tsaftaridis N, Jnani J, Spyropoulos A J Clin Med. 2025; 14(3).

PMID: 39941682 PMC: 11818480. DOI: 10.3390/jcm14031013.

Efficacy and Safety of Andexanet Alfa Versus Four Factor Prothrombin Complex Concentrate for Emergent Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage: A Systematic Review and Meta-Analysis.

Sarhan K, Mohamed R, Elmahdi R, Mohsen Y, Elsayed A, Zayed D Neurocrit Care. 2024; .

PMID: 39379749 DOI: 10.1007/s12028-024-02130-y.

Facial trauma with life-threatening bleeding treated by andexanet alfa administration: A case report.

Shirakawa Y, Jingami N, Ishiguro Y, Minami T, Shinozuka K, Yunoki T Heliyon. 2024; 10(17):e36922.

PMID: 39281456 PMC: 11402178. DOI: 10.1016/j.heliyon.2024.e36922.

Thrombolysis for Ischemic Stroke Despite Recent Ingestion of Direct Oral Anticoagulants - A Growing Dilemma Also in India.

Meinel T, Paramasivan N, Menon B, Fischer U, Seiffge D Ann Indian Acad Neurol. 2024; 27(4):345-351.

PMID: 39196805 PMC: 11418782. DOI: 10.4103/aian.aian_524_24.

A small-molecule hemostatic agent for the reversal of direct oral anticoagulant-induced bleeding.

Desvages M, Borgel D, Adam F, Tu G, Jaouen S, Reperant C Res Pract Thromb Haemost. 2024; 8(4):102426.

PMID: 38882463 PMC: 11179090. DOI: 10.1016/j.rpth.2024.102426.

References
1.
Levy J, Douketis J, Weitz J . Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018; 15(5):273-281. DOI: 10.1038/nrcardio.2017.223. View
2.
Ansell J . Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options. Am J Cardiovasc Drugs. 2016; 16(3):163-70. DOI: 10.1007/s40256-016-0162-7. View
3.
Siegal D, Curnutte J, Connolly S, Lu G, Conley P, Wiens B . Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015; 373(25):2413-24. DOI: 10.1056/NEJMoa1510991. View
4.
Lippi G, Sanchis-Gomar F, Favaloro E . Andexanet: Effectively Reversing Anticoagulation. Trends Pharmacol Sci. 2016; 37(6):413-414. DOI: 10.1016/j.tips.2016.03.002. View
5.
Lu G, Pine P, Leeds J, DeGuzman F, Pratikhya P, Lin J . Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. PLoS One. 2018; 13(3):e0195122. PMC: 5874076. DOI: 10.1371/journal.pone.0195122. View